Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
James F SpicerAurélien MarabelleJean-Francois BaurainNina Louise JebsenDag Erik JøssangAhmad AwadaRebecca S KristeleitDelphine LoiratGeorge LazaridisChristiane JungelsPaal BrunsvigBerit NicolaisenAndrew SaundersHamina PatelJerome GalonFabienne HermitteKetil André CamilioBrynjar MausethVibeke SundvoldBaldur SveinbjørnssonØystein RekdalPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
LTX-315 has an acceptable safety profile, is clinically active, induces changes in the tumor microenvironment and contributes to immune-mediated anticancer activity.